Mindfulness-Based Stress Reduction in Breast Cancer Survivors with Chronic Neuropathic Pain: A Randomized Controlled Trial
Table 2
Unadjusted mean and standard deviations scores at each time point.
Measured time point
Treatment group mean (SD)
Control group mean (SD)
Brief Pain Inventory-Interference
T1
4.60 (2.39)
4.28 (2.40)
T2
4.32 (2.37)
4.08 (2.39)
T3
3.40 (2.34)
3.92 (2.61)
T4
3.49 (2.09)
3.58 (2.61)
Profile of Mood States
T1
67.42 (14.97)
62.72 (13.68)
T2
65.04 (15.44)
63.21 (14.8)
T3
61.42 (15.02)
63.37 (14.89)
T4
62.88 (16.67)
60.92 (16.46)
Patient Global Impression of Change
T1
N/A
N/A
T2
4.29 (1.14)
4.24 (.94)
T3
5.11 (.71)
4.14 (1.15)
T4
5.06 (.98)
4.40 (1.22)
Patient Health Questionnaire-9
T1
9.36 (5.99)
10.48 (6.54)
T2
9.15 (5.71)
9.54 (5.71)
T3
9.49 (5.25)
8.05 (5.12)
T4
7.61 (4.73)
7.85 (5.34)
Five Facet Mindfulness Questionnaire
T1
122.35 (21.72)
127.91(20.67)
T2
125.43 (22.75)
130.04 (22.81)
T3
132.19 (20.20)
130.56 (22.37)
T4
132.94 (23.55)
132.98 (22.79)
Pain Catastrophizing Scale
T1
21.69 (11.77)
19.26 (12.16)
T2
20.09 (10.57)
19.19 (11.54)
T3
15.00 (11.08)
17.60 (11.81)
T4
16.28 (12.09)
14.73 (11.11)
Neuropathic Pain Symptom Inventory
T1
0.40 (0.17)
0.43 (0.16)
T2
0.42 (0.17)
0.42 (0.16)
T3
0.37 (0.14)
0.39 (0.18)
T4
0.37 (0.16)
0.37 (0.17)
Short-Form-12 Health Survey-physical health T-score
T1
32.49 (10.15)
35.19 (10.38)
T2
33.99 (9.61)
36.17 (10.27)
T3
37.59 (10.25)
35.10 (10.56)
T4
36.36 (12.22)
37.21 (12.20)
Short-Form-12 Health Survey-mental health T-score
T1
43.07 (12.13)
46.64 (10.95)
T2
45.94 (12.78)
47.06 (11.10)
T3
48.17 (10.37)
46.69 (11.16)
T4
48.98 (10.69)
48.44 (10.96)
T1: before medical optimization; T2: after randomization; T3: 2 weeks post-MBSR (and equivalent time point for waitlist control group); T4: 3 months post-MBSR (and equivalent time point for waitlist control group).
